Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action.
D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D003994:Bucladesine / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D009539:Nicotinic Acids / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010085:Oxidative Phosphorylation / Q000187:drug effects; D011719:Pyrazines / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D013806:Theophylline / Q000494:pharmacology
D005230:Fatty Acids, Nonesterified; D009539:Nicotinic Acids; D011719:Pyrazines; D003994:Bucladesine; D013806:Theophylline; C027696:acipimox; D009638:Norepinephrine